Serum total and high-density lipoprotein phospholipid levels in a population-based study and relationship to risk of metabolic syndrome and coronary disease

Angiology

Volumn 59, Issue 1, 2008, Pages 26-35

  Hergenç, Gülay ^a   Onat, Altan ^a,e   Sari, Ibrahim ^c   Yazici, Mehmet ^e   Eryonucu, Beyhan ^d   Can, Günay ^a,b  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Cardiology Department   (Turkey)

^e NONE

Author keywords

Coronary heart disease; Metabolic syndrome; Phospholipids; Population based study

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME CHEMISTRY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROTEIN BLOOD LEVEL; RANDOM SAMPLE; RISK; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC);

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PHOSPHOLIPIDS; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; TURKEY;

EID: 39149144463     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319706291145     Document Type: Article

References (25)

1. Tabas I. Lipids and atherosclerosis. In: Bernardi G, Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. 4 th ed. Amsterdam, Holland: Elsevier ; 2002: 573-559.
2. Kitchens RL, Thompson PA, Mundford RS, O' Keefe GE Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res. 2003 ; 44: 2339-2348.
3. Vance JE Assembly and secretion of lipoproteins. In: Bernardi G, Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. 4 th ed. Amsterdam, Holland: Elsevier ; 2002: 505-526.
4. Merill AH, Sandhoff K. Sphingolipids: metabolism and cell signalling. In: Bernardi G, Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. 4 th ed. Amsterdam, Holland: Elsevier ; 2002: 373-407.
5. Jian B., de la Llera-Moya M., Royer L., Rothblat G., Francone O., Swaney JB Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res. 1997 ; 38: 734-744.
6. Subbaiah PV Determination and clinical significance of phospholipids. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook Lipoprotein Testing. Washington, D.C.: AACC Press; 1997: 415-427.
7. Fournier N., de la Llera Moya M., Burkey BF, et al. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res. 1996 ; 37: 1704-1711.
8. Fournier N., Atger V., Cogny B., et al. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis. 2001 ; 157: 315-323.
9. Cui Z., Houweling M. Phosphatidylcholine and cell death. Biochim Biophys Acta. 2002 ; 1585: 87-96.
10. Onat A., Ceyhan K., Basar Ö., Erer B., Toprak S., Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels: a prospective and cross-sectional evaluation. Atherosclerosis. 2002 ; 165: 285-292.
11. Onat A., Hergenç G., Uzunlar B., et al. Serum total phospholipids in Turkish adults: a cross-sectional study on associations with risk of metabolic syndrome and coronary disease. Arch Turk Soc Cardiol. 2004 ; 32: 168-177.
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
13. Takayama M., Itoh S., Nagasaki T., Tanimuzu I. A new enzymatic method for the determination of serum choline-containing phospholipids. Clin Chim Acta. 1977 ; 79: 93-98.
14. American Diabetes Association: clinical practice recommendations. Diabetes Care. 1997 ; 20: 1-70.
15. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-509.
16. Rose G., Blackburn H., Gillum RF, Prineas RJ Cardiovascular Survey Methods. 2 nd ed. Geneva, Switzerland: World Health Organization ; 1982: 124-127.
17. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984 ; 25: 1017-1058.
18. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res. 2003 ; 44: 2339-2348.
19. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003 ; 14: 421-430.
20. Piperi C., Kalofoutis C., Papaevangeliou D., Papapanagiotou A., Lekakis J., Kalofoutis A. The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin Biochem. 2004 ; 37: 377-381.
21. Kunz F., Pechlaner C., Erhart R., Fend F., Muhlberge V. HDL and plasma phospholipids in coronary artery disease. Arterioscler Thromb Vasc Biol. 1994 ; 14: 1146-1150.
22. Horter MJ, Sondermann S., Reinecke H., et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand. 2002 ; 176: 123-130.
23. Fournier N., Paul JL, Atger V., et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscl Thromb Vasc Biol. 1997 ; 17: 2685-2691.
24. Leventhal AR, Chen W., Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem. 2001 ; 276: 44976-44983.
25. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem. 1996 ; 271: 19152-19158.